CLEAR's Patented Breakthrough: 3 Global Patents & 200 Dermatologists Validate Next-Gen Dandruff Solutions
SHANGHAI, April 30, 2025 /PRNewswire/ -- Recently, CLEAR, Unilever's premium professional anti-dandruff brand, held a grand launch event at TANK Shanghai, debuting its first-ever SCALPCEUTICALS PRO RANGE—a groundbreaking series born from over a decade of scientific research by 5 global labs and more than 200 dermatologists. This high-profile industry event not only marks a monumental breakthrough in CLEAR's 50-year journey of scalp care innovation but also heralds a revolutionary new era of 'cellular-level[1] repair' powered by three patented technologies[2]. Furthermore, CLEAR officially announced the launch of the 'Scalp Health Science Expert White Paper,' aiming to propel the beauty and hair care industry into a new phase of scientific advancement through cutting-edge research achievements.
CLEAR SCALPCEUTICALS PRO RANGE Global Launch: Redefining Premium Scalp Care with Technological Innovation
Currently, China's premium scalp care market is experiencing explosive growth, expanding at a rate of 190% and reaching a scale of over 33 billion RMB. Faced with evolving consumer demands and their diverse needs for scalp health, simply focusing on ''cleansing'' is no longer enough to satisfy their desire for a premium experience.
'The key to a healthy scalp lies in fundamental repair at the cellular level.' Elsharkawy Mohamed, Unilever China's Hair Care Marketing Director and Global Vice President of CLEAR, emphasized that Clear is now focusing on cell science and announced the global launch of the brand's first SCALPCEUTICALS PRO RANGE.
Elsharkawy Mohamed also stated, 'This launch event is not only about refreshing our products, but more importantly, about upgrading CLEAR's brand positioning. Our SCALPCEUTICALS PRO RANGE will shift the industry focus from 'basic cleansing' to 'derma-level professional scalp care.' Moving forward, CLEAR will deepen research in scalp cell science, striving to become 'consumers' go-to expert brand for scalp health.'''
Revolutionary Breakthrough at the Cellular Level: CLEAR Unveils the 'Scalp Cell Response Mechanism'
Eric Han, Head of R&D for Unilever Beauty & Wellbeing North Asia, stated: ''In the new era of scalp care, treatment should not remain superficial. CLEAR's technological approach is about 'rebuilding the foundation' by synergistically managing cell metabolism and the scalp microbiome to help restore scalp health.''
Thus, the CLEAR SCALPCEUTICALS PRO RANGE, built upon three patented technologies[1] now introduced five targeted products: The Selenium Disulfide Anti-Dandruff Shampoo incorporates Unilever's proprietary Selenium Disulfide PRO[3] Technology, which strengthens the protein 'skeleton' and 'outer walls' of barrier cells[2] to eliminate and prevent dandruff at its root cause[4], clearing 99% of flakes in just one wash[5], and correcting oiliness, dandruff, and itch in 4 weeks[6]. The Scalp Massage Essence helps repair the scalp barrier and create an invisible shield against dandruff. For recurrent dandruff issues, the Anti-Dandruff Conditioning Shampoo utilizes Piroctone Olamine[7] Technology to not only inhibit and fight dandruff but also to improve the scalp environment, boosting dandruff resistance by 500%[8].
From Product Innovation to Industry Leadership: CLEAR is Pioneering a New Era of Scalp Health.
In addition, during this launch event, CLEAR also initiated the 'Scalp Health Science Expert White Paper.' This initiative aims to provide consumers with more scientific references for scalp health and to propel the entire beauty and hair care industry into a new phase of development. The White Paper is based on Unilever's over fifty years of dedicated scalp research, the latest advancements in scalp science, and the profound insights of 1,100 domestic and international dermatologists on scalp health, focusing on issues such as dandruff, oily scalp, sensitivity, and hair loss. It explains, in an accessible manner, the clinical manifestations, underlying mechanisms, and scientific care recommendations for these conditions.
'CLEAR has dedicated over 50 years to in-depth scalp research. This newly launched SCALPCEUTICALS PRO RANGE represents a vibrant step in the brand's ongoing commitment to its premiumization strategy and its exploration of localized innovation within China,' stated Chen Ge, President of Unilever China. 'China is not only a significant global consumer market but is also becoming an innovation hub for the beauty and hair care industry. By deeply integrating into China's innovation ecosystem, we are upgrading from functionality to science, and from products to systems, thereby injecting continuous momentum into the transformation and sustainable growth of the global industrial chain.'
Notes:
View original content to download multimedia: https://www.prnewswire.com/news-releases/clears-patented-breakthrough-3-global-patents--200-dermatologists-validate-next-gen-dandruff-solutions-302442405.html
SOURCE Unilever
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress
ZYNLONTA® in combination with glofitamab (COLUMVI®) in patients with r/r DLBCL demonstrated clinically meaningful benefit with overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% across 30 efficacy evaluable patients 25 of 26 patients achieving CR remained in CR as of the data cut-off Initial data show the combination is generally well tolerated with a manageable safety profile Company expanding enrollment for LOTIS-7 to 100 patients at 150 µg/kg dose Company to host conference call today at 8:00 a.m. ET/2:00 p.m. CEST LAUSANNE, Switzerland, June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) to be presented at the European Hematology Association 2025 Congress (EHA2025) in Milan, Italy. The Company will host a conference call and webcast featuring LOTIS-7 trial principal investigator and EHA presenting author, Juan Alderuccio, MD, Clinical Site Disease Group Leader, Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine today at 8:00 a.m. ET to discuss the results. To access the conference call, please register here. "The data seen in this study with the combination of ZYNLONTA and glofitamab has shown a manageable safety profile along with strong efficacy data from patients with relapsed or refractory DLBCL, with complete responses observed regardless of prior therapy, including CAR-T," said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. "The combination of these two anti-cancer agents holds significant promise for advancing the treatment landscape and addressing unmet need in patients with these hard-to-treat lymphomas." The presentation highlights updated data as of April 14, 2025, in which r/r LBCL patients received dose levels of 120 µg/kg or 150 µg/kg of ZYNLONTA plus the bispecific antibody glofitamab, with 41 patients evaluable for safety and 30 patients evaluable for efficacy. Key highlights of the LOTIS-7 data presentation are as follows: Best overall response data among the 30 efficacy evaluable patients shows overall response rate (ORR) of 93.3% (28/30 pts) as assessed by Lugano Criteria Complete response (CR) rate of 86.7% (26/30 pts) Of these, 25/26 patients achieving CR remain in CR as of the data cut-off Median time to CR in 120 µg/kg = 80 days Median time to CR in 150 µg/kg = 42 days 12 patients converted from stable disease (SD) or partial response (PR) to CR over time (1 and 11 pts respectively) Of the 6 patients previously treated with CAR-T and undergoing response assessment, 5 achieved a CR Among the 41 safety evaluable patients, the combination was generally well tolerated with a manageable safety profile and no DLTs across dose levels Grade 3 or higher treatment emergent adverse events (TEAEs) observed in > 5% of patients included neutropenia (24.4%), anemia (9.8%), AST increased (7.3%), GGT increased (7.3%), and thrombocytopenia (7.3%) In the 150 µg/kg dose, cytokine release syndrome (CRS) (23.8%), all of which were Grade 1, and immune effector cell-associated neurotoxicity syndrome (ICANS) (4.8%), with one case of Grade 2, were observed In the 120 µg/kg dose, CRS all grades (55%), all of which were Grade 1/2 except one case of Grade 3, and ICANS (10%), with one case of Grade 1 and one case of Grade 2, were observed TEAEs leading to discontinuation included 3 each for ZYNLONTA and glofitamab There were no Grade 5 TEAEs observed "We believe these new data are differentiating and further reinforce the potential of ZYNLONTA plus the bispecific glofitamab to improve outcomes for DLBCL patients who need it most," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This early safety and efficacy data support the ongoing expansion of this study to 100 patients at the 150 µg/kg dose of ZYNLONTA plus glofitamab. We look forward to discussing the results with Dr. Alderuccio during our conference call today in addition to the presentation of the data set across two key conferences." This data will be shared at EHA2025 during a poster presentation on June 14 at 6:30 p.m. CEST and also as an oral encore presentation at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Friday, June 20 at 9:00 a.m. ET. The Company plans to share additional data before the end of 2025. Conference Call InformationTo access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at The archived webcast will be available for 30 days following the call. About LOTIS-7LOTIS-7 is a Phase 1b global multicenter, multi-arm study in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) including Part 1 (dose escalation) and Part 2 (dose expansion). The three dosing arms include ZYNLONTA plus polatuzumab vedotin, ZYNLONTA plus glofitamab, and ZYNLONTA plus mosunetuzumab T-cell-engaging bispecific monoclonal antibodies (BsAbs). Enrollment in LOTIS-7 includes Part 1 of the study with a 3+3 dose escalation in 3L/3L+ heavily pre-treated patients with ZYNLONTA doses starting at 90 µg/kg and then proceeding to 120 µg/kg and 150 µg/kg. Part 2 includes dose expansion in 2L/2L+ large B-cell lymphoma in the ZYNLONTA plus glofitamab arm at dose levels determined from Part 1 (120 µg/kg and 150 µg/kg of ZYNLONTA plus the approved dosing of glofitamab). Primary endpoints of the study include safety and tolerability. Secondary efficacy endpoints include ORR, DOR, CRR, PFS, RFS, and OS as well as pharmacokinetics and immunogenicity. For more information about the LOTIS-7 trial, visit (NCT04970901). About ZYNLONTA® ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Please see full prescribing information including important safety information about ZYNLONTA at ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London and New Jersey. For more information, please visit and follow the Company on LinkedIn. ZYNLONTA® is a registered trademark of ADC Therapeutics SA. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential of ZYNLONTA® in combination with the bispecific antibody glofitamab, including the reproducibility and durability of any favorable results initially seen in patients dosed to date, and the Company's research, development and regulatory plans, including the timing and results of clinical trials and the timing and outcome of regulatory submissions. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA® revenue in the United States; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS:Investor RelationsMarcy GrahamADC 650-667-6450 Media RelationsNicole RileyADC 862-926-9040 View original content to download multimedia: SOURCE ADC Therapeutics SA Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
36 minutes ago
- Yahoo
David Beckham Launches BEEUP - The Next-Gen, Honey-Powered Snack Brand for Active Kids and Families
Exclusively available now at Target Stores Across the Country LOS ANGELES, June 16, 2025 /PRNewswire/ -- BEEUP, a next-generation snack brand, launches in Target stores across the country today with its debut line of honey-powered fruit snacks. BEEUP is co-founded by David Beckham, former athlete, entrepreneur and President and Co-owner of Inter Miami CF soccer club; and Shaun Neff, serial entrepreneur behind breakthrough brands such as SUN BUM, BÉIS, and Moon Oral Care. BEEUP is inspired by honey's ability to provide natural energy that tastes as good as it performs, and with 40-year CPG vet Mike Keown as CEO, BEEUP is looking to disrupt the U.S. snack market; a market projected to hit $53.33 billion in revenue by the end of 2025. BEEUP's reason for existing starts with honey. The idea was born from David's well-documented love for beekeeping, having spent hours by his hives, caring for the bees, and harvesting honey. As a father and former pro athlete, David was always looking for wholesome snacks for his family and was amazed as he learnt about the nutritious properties of honey. All BEEUP snacks harness honey's superfood power to fuel kids and families to be their best through busy mornings, after-school sports, and everything in between. This nutrient-dense powerhouse ingredient offers a naturally sweet upgrade from refined sugars and delivers real energy for real life. The reimagined fruit snack line is non-GMO, free from synthetic dyes, fake flavors, and contains an excellent source of Vitamins A, C, and E. "Beekeeping began as a hobby with my sons, but quickly grew into a deep appreciation for honey as a powerful superfood that provides natural energy," said David Beckham, Co-Founder of BEEUP. "I am excited to make this wholesome, nutritious ingredient available for active kids and families in the form of these incredible BEEUP snacks. Whether prepping for a game, performance, or the playground, we've made BEEUP to offer families natural energy they could feel good about eating." "From my first conversation with David, it was clear that his passion for beekeeping and honey had sparked something special," said Shaun Neff, Co-Founder of BEEUP. "We saw a unique opportunity to disrupt the kids' snack space with a brand powered by real honey, made for active kids and with a strong connection to youth sports. It's been an incredible journey working with David and bringing this brand to life." BEEUP's new 10-pack of delicious fruit snacks will be available in three juicy flavors, including Very Berry, Tropical Mix, and Sour Watermelon at Target stores across the country, and on the BEEUP website for an MSRP of $4.99. Learn more at or follow along on Instagram @beeupsnacks. About BEEUPBEEUP is the snack brand for active kids, powered by real honey. Co-founded by David Beckham and Shaun Neff, BEEUP is shaking up the kids' snack aisle with standout design, bold flavors, and simple ingredients, all rooted in the natural energy of honey. BEEUP fuels active families with wholesome, feel-good energy. Learn more at or follow along on Instagram @beeupsnacks. MEDIA CONTACTOlivia FloresBEEUP@ View original content to download multimedia: SOURCE BEEUP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
"Luminous Path, Shared Stride - Brazil and China"
SHANGHAI, June 16, 2025 /PRNewswire/ -- Brazil's delegation embarked on a landmark visit to Shanghai, exploring cutting-edge advancements in healthcare and aesthetic medicine. The delegation's first stop was Zhongshan Hospital, a world-renowned medical institution consistently ranked among China's top three hospitals. As a pioneer in robotic surgery and organ transplantation, the 1800-bed facility boasts 46 national key disciplines and has pioneered over 100 innovative medical techniques. At Moyom Biotech, delegates immersed in authentic Chinese culture through Dragon Boat Festival traditions. The visit concluded at Yestar Aesthetic Medicine Hospital, Asia's largest chain of aesthetic medical institutions with over 200 centers across 18 countries. In 2024 alone, Yestar achieved remarkable commercial success with: ¥10 billion in annual revenue 38% year-on-year growth in international markets Over 500,000 successful aesthetic procedures performed This exchange has set a new benchmark for Brazil-China collaboration, where medical excellence meets cultural synergy. View original content to download multimedia: SOURCE SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD Sign in to access your portfolio
